shr7280
Small moleculeexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 25, 2020 (NCT04417972)
Timeline
Indications
Mechanism of action
GNRHR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06969664 | Phase 1 | May 19, 2025 | Hengrui Therapeutics, Inc. |
| NCT06949124 | Phase 1 | Apr 28, 2025 | Hengrui Therapeutics, Inc. |
| NCT06408948 | Phase 1 | Jun 7, 2024 | Hengrui Therapeutics, Inc. |
| NCT05994378 | Phase 3 | Aug 29, 2023 | Hengrui Therapeutics, Inc. |
| NCT05868057 | Phase 1 | May 23, 2023 | Hengrui Therapeutics, Inc. |
| NCT05442827 | Phase 2/Phase 3 (Phase 3) | Jul 30, 2022 | Hengrui Therapeutics, Inc. |
| NCT05082233 | Phase 2 | Oct 20, 2021 | Hengrui Therapeutics, Inc. |
| NCT04995042 | Phase 1 | Aug 25, 2021 | Hengrui Therapeutics, Inc. |
| NCT04554043 | Phase 1 | Sep 10, 2020 | Hengrui Therapeutics, Inc., Qingdao University |
| NCT04417972 | Phase 1/Phase 2 (Phase 2) | May 25, 2020 | Hengrui Therapeutics, Inc., Peking University |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 10 | 10 | 3 | 2020 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Qingdao University | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1